Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biomedical Engineering

Background:

• Platelets play a key role in stent thrombosis with drug-eluting stents.
• The impact of eluted drugs on platelet function remains largely unknown.

Purpose of the Study:

• To investigate the effects of rapamycin on platelet aggregation.
• To assess how rapamycin influences aspirin's antiplatelet efficacy.

Main Methods:

• Platelet-rich plasma was used to measure aggregation induced by adenosine diphosphate (ADP).
• Rapamycin was tested at various concentrations.
• Aspirin's inhibitory effect on platelet aggregation was evaluated alongside rapamycin.

Main Results:

• Higher rapamycin concentrations (>10 ng/mL) significantly enhanced ADP-induced platelet aggregation.
• This enhancement was statistically significant at 50 ng/mL and 100 ng/mL (P = 0.005 and P = 0.04).
• Rapamycin reduced aspirin's ability to inhibit platelet aggregation at higher concentrations.

Conclusions:

• Elevated concentrations of rapamycin can potentiate platelet aggregation.
• Rapamycin diminishes the antiplatelet effectiveness of aspirin.
• These findings have implications for understanding drug-eluting stent-related thrombosis.